Use of composition for enhancing anticancer effect, comprising ERRy inhibitor as active ingredient
AssigneeNovmetapharma Co., Ltd.
InventorsKeun Gyu Park, In Kyu Lee, Sung Jin Cho, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Chin, Yong Hyun Jeon, Jin A Kim, Dong Su Kim, Hoe Yune Jung
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.
Claims7
A method for diagnosis and treatment of sorafenib-resistant liver cancer, comprising the following steps:
- (a) measuring an expression level of mRNA of an estrogen-related receptor γ (ERRγ) gene or a protein expressed therefrom in a biological sample isolated from a test patient with liver cancer;
- (b) comparing the measured expression level of the ERRγ mRNA and/or the measured level of ERRγ protein of the test patient of step (a) with a reference expression level of ERRγ mRNA and/or a reference level of ERRγ protein, said reference expression level of ERRY mRNA and/or a reference level of ERRγ protein being obtained from a reference patient with a liver cancer other than sorafenib-resistant liver cancer,
- wherein a higher measured expression level of the ERRγ mRNA than the reference expression level and/or a higher measured level of ERRγ protein than the reference level indicates that the test patient has sorafenib-resistant liver cancer;
- and
- (c) administering to the test patent who is determined to have sorafenib-resistant liver cancer, (i) an agent capable of inhibiting ERRγ protein activity or ERRγ gene expression;
- (ii) a combination of sorafenib and an agent capable of inhibiting ERRγ protein activity or ERRγ gene expression.
A method selected from the group consisting of:
- (a) preventing or inhibiting a development of sorafenib resistance in a liver cancer patient who is prescribed for sorafenib treatment or underwent sorafenib treatment;
- and
- (b) enhancing sorafenib treatment of a liver cancer patient,
- said method comprising administering to the liver cancer patient an effective amount of an inverse agonist against estrogen-related receptor γ (ERRγ),
- wherein the inverse agonist against ERRγ is a compound of the following Formula 1 or a pharmaceutically acceptable salt thereof:
A method of treating liver cancer in a subject in need thereof, comprising:
- administering an effective amount of an inverse agonist against estrogen-related receptor γ (ERRγ),
- wherein the inverse agonist against ERRγ is a compound of the following Formula 1 or a pharmaceutically acceptable salt thereof:
Dependencies are inferred from the claim text.